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A B S T R A C T
Background: Gender differences in symptomatology in chronic schizophrenia and first episode psychosis
patients have often been reported. However, little is known about gender differences in those at risk of
psychotic disorders. This study investigated gender differences in symptomatology, drug use,
comorbidity (i.e. substance use, affective and anxiety disorders) and global functioning in patients
with an at-risk mental state (ARMS) for psychosis.
Methods: The sample consisted of 336 ARMS patients (159 women) from the prodromal work package of
the EUropean network of national schizophrenia networks studying Gene-Environment Interactions
(EU-GEI; 11 centers). Clinical symptoms, drug use, comorbidity and functioning were assessed at first
presentation to an early detection center using structured interviews.
Results: In unadjusted analyses, men were found to have significantly higher rates of negative symptoms
and current cannabis use while women showed higher rates of general psychopathology and more often
displayed comorbid affective and anxiety disorders. No gender differences were found for global
functioning. The results generally did not change when corrected for possible cofounders (e.g. cannabis
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S. Menghini-Müller et al. / European Psychiatry 59 (2019) 52–59 53use). However, most differences did not withstand correction for multiple testing.
Conclusions: Findings indicate that gender differences in symptomatology and comorbidity in ARMS are
similar to those seen in overt psychosis and in healthy controls. However, observed differences are small
and would only be reliably detected in studies with high statistical power. Moreover, such small effects
would likely not be clinically meaningful.
© 2019 Published by Elsevier Masson SAS.1. Introduction
Gender differences in schizophrenia have attracted the
attention of scientific research for more than a century. Kraepelin
had already reported that women are older at first admission for
dementia praecox compared to men [1]. Most studies to date
confirm these findings [2]. Findings on severity of psychopatho-
logical symptoms are less conclusive, with some authors
suggesting that men have more severe negative symptoms
while women show more severe affective and specific psychotic
symptoms [2]. However, only few gender differences in
psychopathology of first episode schizophrenia were found in
the ABC study, and these were not significant after correction for
multiple testing [3,4]. With regard to substance abuse, available
evidence suggests that men have a higher prevalence of
substance abuse and higher levels of comorbidity compared to
women. Additionally, studies examining gender differences in
premorbid and social functioning have found higher functioning
in women [2].
In the past two decades, the field of early detection of
psychosis has received growing scientific and clinical interest [5],
albeit that only few methodologically sound studies have
considered gender differences in patients with an at-risk mental
state (ARMS) for psychosis. These studies have thus far yielded
inconsistent results. With regard to symptomatology, most
studies described in the comprehensive review of Barajas et al.
[6] reported no gender differences in ARMS patients. Neverthe-
less, some studies found more severe negative symptoms in men,
and other studies found lower levels of social functioning and a
longer duration of untreated illness in men compared to women
[6]. A more recent review published by Riecher-Rössler et al. [2]
suggests that gender differences in the symptomatology of
patients at risk are small and comparable to those seen in the
general population. Thus, in a representative worldwide general
population sample of 72,933 subjects, men in general had a
greater propensity to substance, alcohol and cannabis abuse,
while women had more affective symptoms, depression and
anxiety [7].
In addition to the at-risk signs and symptoms for psychosis,
many ARMS patients suffer from comorbid non-psychotic mental
disorders, in particular depression and anxiety disorders [8,9]. To
our knowledge, only two studies have investigated gender
differences in comorbid depressive and anxiety diagnoses in
ARMS patients at baseline. Kline et al. [10] examined a cohort of
764 ARMS patients (women, n = 329; 43%) from the North
American Prodrome Longitudinal Study (NAPLS-2), and observed
a significantly higher lifetime prevalence of depression in women
than men (64% vs. 56%). No significant gender differences in
comorbid affective and anxiety disorders were observed in the
study of Rietschel et al. [11].
To further elucidate these issues, the present study investi-
gated gender differences in symptomatology, drug use, comor-
bidity (i.e. substance use, affective and anxiety disorders) and
global functioning in a large multinational sample of ARMS
patients. Based on previous and our own findings, we expected
to find no significant differences between ARMS men and
women.2. Methods
2.1. Setting and recruitment
The data analysed in this study were collected within the
multicenter EUropean Gene-Environment Interactions (EU-GEI)
study, from May 1, 2010 to April 30, 2015. The aim of EU-GEI study
is to identify the interactive genetic, clinical and environmental
determinants of schizophrenia [12]. The overall design of the
study was naturalistic, longitudinal and prospective, consisting of
a baseline and two follow-up time points. For the current
analyses, only baseline, i.e. at intake into the study, data were
used and only patients with complete data on cannabis frequency
were included.
ARMS patients were recruited from 11 Early Detection and
Intervention Centers, nine in Europe (London, Amsterdam, The
Hague, Vienna, Basel, Cologne, Copenhagen, Paris, Barcelona), one
in Brazil (Saõ Paulo), and one in Australia (Melbourne). Referrals
were accepted from primary health care services, mental health
professionals, or from the subject or their family. Study intake
corresponds to the admission date in the early detection service.
All participants were screened with an inclusion/exclusion
checklist (see below).
The protocol of the EU-GEI study was approved by the
institutional review boards of all study sites. EU-GEI was
conducted in accordance with the Declaration of Helsinki. The
Medical Ethics Committees of all participating sites approved the
study protocol.
2.2. Inclusion and exclusion criteria
Inclusion criteria for EU-GEI were: aged 18–35; being at-risk for
psychosis as defined by the Comprehensive Assessment of At-Risk
Mental State (CAARMS) [13]; adequate language skills local to each
center; and consent to study participation.
The exclusion criteria were: prior experience of a psychotic
episode of more than 1-week as determined by the CAARMS [13]
and Structural Clinical Interview for DSM Disorders (SCID) [14];
previous treatment with an antipsychotic for a psychotic episode;
and IQ < 60.
2.3. Determination of ARMS status
The CAARMS, used to identify ARMS patients [13], is a semi-
structured interview that encompasses psychotic symptoms and
a range of other psychopathological symptoms occurring in
emerging psychotic disorder. Individuals were classified as
being in an ARMS for psychosis if they met at least one of the
following risk criteria: (i) Vulnerability Group (a first-degree
relative with a psychotic disorder or diagnosed with schizotypal
personality disorder in combination with a significant drop in
functioning); (ii) Attenuated Psychotic Symptoms (APS) (psy-
chotic symptoms sub-threshold either in intensity or frequen-
cy); (iii) Brief Limited Psychotic Symptoms (BLIPS) (recent
episode of brief psychotic symptoms that spontaneously
resolved within 1 week). The full criteria can be found in Yung
et al. [13].
54 S. Menghini-Müller et al. / European Psychiatry 59 (2019) 52–592.4. Assessment of sociodemographic characteristics and medication
Sociodemographic characteristics were obtained using the
modified Medical Research Council (MRC) sociodemographic
schedule [15]. Data on psychiatric medication were assessed with
a medical history questionnaire, designed by the EU-GEI group.
2.5. Assessment of psychopathology
Psychopathological symptoms were assessed using the
expanded version of the Brief Psychiatric Rating Scale
(BPRS-E) [16], the Scale for the Assessment of Negative
Symptoms (SANS) [17], the Comprehensive Assessment of
At-Risk Metal State (CAARMS) [13], the Montgomery-Åsberg
Depression Rating Scale (MADRS) [18], and the Young Mania
Rating Scale (YMRS) [19]. Genders differences were investi-
gated using the following subscales:
BPRS-E: Activation, Positive symptoms, Negative symptoms,
Affect, Disorganization as defined by Shafer et al. [16] and the total
score
SANS: Affective Flattening, Alogia, Asociality-Anhedonia, Avo-
lition-Apathy, Inattention and the total score [17]
CAARMS: Behavioral change, Cognitive change - attention/
concentration, Emotional disturbance, Motor/physical
changes, Negative symptoms, Positive symptoms, General
Psychopathology[20]
MADRS: Detachment, Negative Thoughts, Neurovegetative,
Sadness as defined by Quilty et al. [21] and the total score
YMRS: Total score [19]
2.6. Assessment of comorbidity, drug use and functioning
Affective and anxiety disorders were assessed with the
Structured Clinical Interview for the Diagnostic Manual of
Psychiatric Disorders-IV (DSM-IV/SCID) [14]. Current use, abuse
and dependence of cannabis, amphetamine (e.g. speed, ecstasy),
cocaine, and hallucinogens (e.g. lysergic acid diethylamide (LSD),
“magic mushrooms”) were assessed using the Cannabis Experience
Questionnaire [22]. For cannabis, the frequency of use was
additionally assessed. Participants were defined as being current
users of a substance if they identified themselves as such or if they
reported any use in the preceding month.
The general level of functioning was assessed with the
GAF scale [23].Table 1
Sociodemographic and clinical characteristics.
Men (n = 177) Women (n = 159)
Age 22.8 (5.13) 22.0 (4.70) 
Years of education 14.4 (3.29) 14.4 (2.84) 
Highest level of education 
School, no qualifications 16 (9.88%) 11 (8.21%)
School, with qualifications 51 (31.5%) 47 (35.1%)
Tertiary, Further 50 (30.9%) 38 (28.4%)
Vocational 24 (14.8%) 17 (12.7%)
Higher (undergraduate) 18 (11.1%) 17 (12.7%)
Higher (postgraduate) 3 (1.85%) 4 (2.99%)
Living with 
Alone 28 (15.8%) 23 (14.5%)
Other 56 (31.6%) 61 (38.4%)
Parents/family 93 (52.5%) 75 (47.2%)
Antipsychotics currently 15 (10.3%) 15 (11.3%) 
Antidepressants currently 41 (28.1%) 43 (32.3%) 
Hypnotics currently 2 (1.37%) 2 (1.50%) 
Continuous variables are described by means and standard deviations in parentheses.
a P-value corrected for multiple testing.
b P-value corrected for age and multiple testing.
* P < 0.05.2.7. Statistical analyses
All statistical analyses were carried out using R environment for
statistical computing [24]. Because observations were non-
independent, that is, observations from the same center were
more similar than observations from different centers, gender
differences were analysed using mixed effects models including
gender as a fixed effects factor and randomly varying intercepts per
center to account for the clustering in the data. We used linear
mixed effects models for continuous measures (i.e. age, years of
education, functioning and psychopathology scales), mixed effects
logistic regression models for binary measures (i.e. psychiatric
diagnoses, drug use and psychiatric medication), ordinal mixed
effects models for ordered categorical measures (i.e. cannabis
frequency and highest level of education) and mixed effects
multinomial logistic regression for unordered categorical meas-
ures (i.e. living situation). We analysed gender differences in the
frequency of use of antipsychotics, antidepressants and hypnotics.
Cannabis frequency and age were included as covariates in models
estimating gender differences in psychopathology and living
situation, respectively. Continuous dependent variables were
z-transformed before inclusion to models and gender was included
as a binary variable with 0 and 1 describing men and women,
respectively. Thus, the regression coefficient for gender
described the standardized mean difference of women compared
to men. P-values were adjusted for multiple testing across all of the




In total, 345 ARMS patients participated in the EU-GEI study. The
sample of this study consisted of 336 ARMS patients (177 men, 159
women). 9 ARMS patients had not complete data on cannabis
frequency and were excluded. Sociodemographic and clinical
characteristics are presented in Table 1. Male patients were
significantly older than female patients in unadjusted analyses
(P = 0.011). The significance of this effect disappeared after
correction for multiple testing (P = 0.175). There were no significant
gender differences in ARMS patients with regard to years of
education, highest level of education, living situation and current
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Table 2 shows the results of the linear mixed effects models
using symptomatology as continuous dependent variable and
gender as fixed effects factor. Standardized mean differences
(SMD) and 95% confidence intervals of the psychopathological
syndrome scales are additionally presented in Fig. 1.
Female ARMS patients showed significantly less severe BPRS
“Negative Symptoms” (b = 0.22, P = 0.046), more CAARMS
“General psychopathology” (b = 0.30, P = 0.007) and trendwise less
SANS “Affective Flattening” (b = 0.20, P = 0.073) than male ARMS
patients in uncorrected analyses. These differences becameTable 2








BPRS Activation 3.8 (1.7) 3.5 (1.3) 319 0.15 [-0.37;
0.07]
BPRS Affect 7.7 (3.2) 8.1 (3.1) 319 0.02 [-0.20; 0.25] 
BPRS Disorganization 4.0 (1.5) 3.6 (1.3) 319 0.13 [-0.35;
0.09]
BPRS Negative Symptoms 5.4 (2.7) 4.7 (2.0) 319 0.22 [-0.44;
-0.01]
BPRS Positive Symptoms 7.7 (3.3) 7.3 (3.0) 318 0.09 [-0.31;
0.12]
BPRS total score 44.2
(10.8)
43.0 (9.7) 319 0.07 [-0.29;
0.14]
CAARMS
CAARMS Behavioral change 7.8 (4.2) 8.2 (3.7) 332 0.07 [-0.15; 0.30] 
CAARMS Cognitive change,
attention/concentration
3.2 (1.8) 3.1 (1.8) 332 0.03 [-0.20; 0.25] 






16.1 (6.0) 333 0.30 [0.08; 0.52] 
CAARMS Motor/physical
changes
2.1 (2.7) 2.3 (2.5) 329 0.18 [-0.04; 0.40] 
CAARMS Negative symptoms 6.7 (3.7) 7.2 (3.1) 331 0.10 [-0.11; 0.34] 
CAARMS Positive symptoms 10.0
(3.9)
9.7 (4.4) 334 0.00 [-0.21; 0.21] 
GAF
GAF Disability, impairment 55.6
(12.4)
55.2 (12.4) 328 0.05 [-0.18; 0.26] 
GAF Symptoms 54.9
(10.3)
55.3 (10.1) 313 0.07 [-0.16; 0.29] 
MADRS
MADRS Detachment 6.4 (3.2) 6.2 (3.2) 323 0.07 [-0.29;
0.15]
MADRS Negative Thoughts 3.0 (2.3) 3.2 (2.1) 322 0.07 [-0.15; 0.31] 
MADRS Neurovegetative 5.0 (3.1) 5.4 (3.3) 323 0.14 [-0.09; 0.36] 
MADRS Sadness 4.2 (2.7) 4.4 (2.8) 323 0.03 [-0.19; 0.26] 
MADRS total score 18.6
(9.3)
19.2 (9.1) 323 0.06 [-0.16; 0.28] 
SANS
SANS Affective Flattening 4.0 (4.7) 2.9 (4.2) 325 0.20 [-0.42;
0.02]
SANS Alogia 1.8 (2.5) 1.0 (2.1) 325 0.17 [-0.38;
0.04]
SANS Asociality-Anhedonia 6.1 (4.6) 5.1 (4.0) 324 0.16 [-0.39;
0.06]
SANS Avolition-Apathy 3.5 (2.9) 3.4 (2.6) 325 0.06 [-0.15; 0.27] 
SANS Inattention 0.9 (1.5) 1.1 (1.7) 321 0.20 [-0.02; 0.41] 
SANS total score 16.4
(11.5)
13.5 (10.8) 325 0.14 [-0.35;
0.08]
YMRS
YMRS total score 4.4 (5.1) 3.3 (3.8) 316 0.17 [-0.38;
0.05]
BPRS: Brief Psychiatric Rating Scale; CAARMS: Comprehensive Assessment of At-Risk M
Depression Rating Scale;
SANS: Scale for the Assessment of Negative Symptoms; YMRS: Young Mania Rating Sc
a P-value corrected for cannabis use and multiple testing.
* P < 0.05.
** P < 0.01.significant when corrected for cannabis use (BPRS: b = 0.24,
P = 0.032; CAARMS: b = 0.33, P = 0.003, SANS: b = 0.22, P = 0.048).
However, when p-values were additionally adjusted for multiple
testing by using the FDR procedure, differences in negative
symptoms and general psychopathology were no longer signifi-
cant. There were no gender differences in ARMS patients with
regard to global functioning.
3.3. Gender differences in drug use and comorbidity
Table 3 shows the ORs for associations of gender with comorbid








0.10 [-0.32; 0.12] 0.191 0.396 0.700
0.06 [-0.16; 0.29] 0.848 0.613 0.866
0.09 [-0.32; 0.13] 0.241 0.412 0.700
0.24 [-0.46; -0.02] 0.046* 0.032* 0.181
0.05 [-0.27; 0.17] 0.406 0.663 0.886
0.03 [-0.24; 0.19] 0.498 0.798 0.928
0.11 [-0.11; 0.33] 0.520 0.336 0.700
0.04 [-0.19; 0.26] 0.804 0.740 0.925
0.04 [-0.26; 0.18] 0.862 0.751 0.925
0.33 [0.12; 0.56] 0.007** 0.003** 0.087
0.19 [-0.03; 0.41] 0.107 0.088 0.312
0.12 [-0.10; 0.35] 0.347 0.298 0.700
0.02 [-0.20; 0.23] 0.993 0.862 0.985
0.01 [-0.22; 0.22] 0.682 0.960 1.000
0.05 [-0.18; 0.28] 0.570 0.678 0.886
0.07 [-0.29; 0.16] 0.546 0.568 0.846
0.10 [-0.12; 0.35] 0.528 0.374 0.700
0.17 [-0.06; 0.39] 0.228 0.147 0.410
0.03 [-0.19; 0.26] 0.759 0.773 0.927
0.08 [-0.14; 0.31] 0.581 0.464 0.724
0.22 [-0.45; 0.00] 0.073 0.048* 0.238
0.17 [-0.39; 0.04] 0.120 0.121 0.381
0.18 [-0.41; 0.05] 0.157 0.125 0.381
0.08 [-0.13; 0.30] 0.576 0.449 0.724
0.20 [-0.02; 0.41] 0.069 0.079 0.312
0.15 [-0.37; 0.07] 0.216 0.191 0.471
0.09 [-0.30; 0.12] 0.131 0.415 0.700
ental State; GAF: Global Assessment of Functioning; MADRS: Montgomery Åsberg
ale; CI = 95% Confidence Interval.
Fig. 1. Standardized mean differences (d) and 95% confidence intervals of the Brief Psychiatric Rating Scale (BPRS), Comprehensive Assessment At-Risk Mental State
(CAARMS), Global Assessment of Functioning (GAF), Montgomery-Åsberg Depression Rating Scale (MADRS), Scale for the Assessment of Negative Symptoms (SANS) and
Young Mania Rating Scale (YMRS). The bold vertical line at zero represents the severity of symptomatology in men. Differences are significant if the 95% confidence
interval (horizontal line) does not overlap with zero.
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higher proportion of current cannabis users (OR, 0.53; 95% CI 0.32
to 0.88; P = 0.015) and a higher current frequency of cannabis use
than women (P = 0.008).
With regard to broad diagnostic categories, women were
significantly more often diagnosed with any lifetime affective
disorder (OR, 1.72; 95% CI 1.05–2.81; P = 0.032) and any current
anxiety disorder (OR, 1.66; 95% CI 1.04–2.64; P = 0.034). With
regard to specific diagnoses, women were more frequently
diagnosed with a past major depressive episode (OR, 1.78; 95%
CI 1.11–2.88; P = 0.018), a current panic disorder with (OR, 2.57; 95%
CI 1.14–5.81; P = 0.024) and without agoraphobia (OR, 2.00; 95% CI
1.12–3.55; P = 0.019), current specific phobia (OR, 4.26; 95%
CI 1.90–9.51; P = < 0.001) and current PTSD (OR, 2.25; 95%
CI 1.07–4.74; P = 0.033). However, when adjusted for multiple
testing, only current specific phobia remained significantly
associated with gender (P = 0.031).
4. Discussion
The current study investigated gender differences in socio-
demographic variables, symptomatology, drug use, comorbidity(i.e. substance use, affective and anxiety disorders) and global
functioning in 336 ARMS patients presenting for the first time at an
early detection service in a multi-national study. Unadjusted
analyses indicated higher severity of negative symptoms (i.e. BPRS
negative symptoms, SANS affective flattening) and current
cannabis use in men while women showed higher severity of
general psychopathology (CAARMS) and suffered more from
comorbid affective (i.e. lifetime affective disorders, past major
depressive episode) and anxiety disorders (e.g. panic, panic with
agoraphobia, specific phobia, PTSD). However, when corrected for
multiple testing and confounding variables, these differences were
no longer significant except for higher lifetime rates of specific
phobia in women.
Regarding sociodemographic variables, our results are in
agreement with an earlier study on ARMS patients [11] with the
exception of age and living situation. While Rietschel et al. [11]
found no gender difference in age, the current study found male
ARMS patients to be significantly older than female ARMS patients
but only if statistically not corrected for multiple testing. Rietschel
et al. [11] suggest that male ARMS patients are living more
frequently with their parents or other relatives than female ARMS
patients whereas the present study did not find any significant
Table 3
Gender differences in drug use and comorbidity.
SCID Diagnosis Men (n = 177) Women (n = 159) N Odds ratio [CI] P-value uncorrected P-value correcteda
Drug use
Cannabis current use 56 (31.6%) 31 (19.5%) 336 0.53 [0.32; 0.88] 0.015* 0.175
Cannabis current frequency 336 0.008** 0.168
none 121 (68.4%) 128 (80.5%)
only once or twice 2 (1.13%) 2 (1.26%)
a few times each year 7 (3.95%) 10 (6.29%)
a few times each month 12 (6.78%) 5 (3.14%)
(more than) once a week 9 (5.08%) 2 (1.26%)
every day 26 (14.7%) 12 (7.55%)
Cannabis lifetime dependence 36 (35.6%) 21 (26.9%) 179 0.72 [0.38; 1.40] 0.337 0.714
Amphetamines current use 30 (26.1%) 17 (21.0%) 196 0.74 [0.37; 1.46] 0.383 0.721
Amphetamines current abuse 2 (1.7%) 2 (2.5%) 196 1.43 [0.20; 10.48] 0.725 0.910
Amphetamines current dependence 2 (1.7%) 3 (3.7%) 196 2.23 [0.42; 11.97] 0.351 0.714
Cocaine current use 28 (24.3%) 11 (13.6%) 196 0.49 [0.23; 1.05] 0.069 0.312
Cocaine current abuse 2 (1.7%) 2 (2.5%) 196 1.52 [0.39; 5.84] 0.544 0.808
Cocaine current dependence 2 (1.7%) 1 (1.2%) 196 0.69 [0.16; 2.98] 0.619 0.829
Hallucinogens current use 16 (13.9%) 9 (11.1%) 196 0.81 [0.34; 1.89] 0.622 0.829
Hallucinogens current abuse 1 (0.9%) 1 (1.2%) 196 1.71 [0.42; 6.96] 0.456 0.788
Hallucinogens current dependence 1 (0.9%) 0 (0.0%) 196 0.00 [0.00; 0.00] 1.000 1.000
Affective disorders
Lifetime affective disorder 106 (59.9%) 122 (76.7%) 336 1.72 [1.05; 2.81] 0.032* 0.198
Current major depressive episode 48 (27.6%) 59 (38.6%) 327 1.52 [0.93; 2.46] 0.093 0.329
Past major depressive episode 71 (41.8%) 84 (57.5%) 316 1.78 [1.11; 2.88] 0.018* 0.175
Current dysthymic disorder 10 (6.0%) 10 (6.7%) 317 0.89 [0.37; 2.10] 0.782 0.945
Past manic episode 5 (3.0%) 7 (4.7%) 319 1.64 [0.54; 5.00] 0.385 0.721
Current hypomaniac episode 3 (1.9%) 1 (0.7%) 306 0.37 [0.04; 3.63] 0.395 0.721
Past hypomaniac episode 8 (4.8%) 9 (6.1%) 314 1.24 [0.47; 3.26] 0.665 0.868
Anxiety disorders
Current anxiety disorder 71 (40.1%) 94 (59.1%) 336 1.66 [1.04; 2.64] 0.034* 0.198
Current panic disorder 26 (15.7%) 44 (29.5%) 315 2.00 [1.12; 3.55] 0.019* 0.175
Current panic disorder with agoraphobia 9 (5.9%) 21 (15.3%) 290 2.57 [1.14; 5.81] 0.024* 0.194
Current agoraphobia without history of panic disorder 3 (1.7%) 3 (1.9%) 336 0.90 [0.18; 4.53] 0.895 0.988
Current social phobia 23 (13.6%) 38 (25.5%) 318 1.66 [0.92; 3.01] 0.092 0.329
Current specific phobia 7 (4.2%) 29 (19.3%) 318 4.26 [1.90; 9.51] <0.001*** 0.031*
Current generalized anxiety disorder 14 (8.5%) 22 (14.6%) 315 1.69 [0.84; 3.40] 0.144 0.419
Current obsessive compulsive disorder 16 (10.3%) 13 (9.3%) 295 0.99 [0.46; 2.13] 0.987 1.000
Current post traumatic stress disorder 11 (6.6%) 23 (15.3%) 317 2.25 [1.07; 4.74] 0.033* 0.198
SCID: Structured Clinical Interview for the Diagnostic Manual of Psychiatric Disorders DSM-IV; CI: 95% Confidence Interval.
a P-value corrected for multiple testing.
* P < 0.05.
** P < 0.01.
*** P < 0.001.
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average age in our sample. Another possibility is that this gender
difference is dependent on the country or region the sample is
taken from.
Regarding psychopathology, our findings were in line with a
previous study of our own group that reported no gender
differences in psychopathology, neither in ARMS nor in FEP
patients, when corrected for multiple testing [26]. Furthermore,
Willhite et al. [27] also found no significant gender differences in
ratings of any of the symptoms of the Scale of Prodromal
Symptoms (SOPS) in high-risk patients. A possible explanation
may be that gender differences in the symptoms are so small that
they can only be reliably detected in studies with very high
statistical power (i.e. in very large datasets or in meta-analyses).
However, such small effects would likely not be clinically
meaningful.
Regarding drug use and comorbidity, male ARMS patients
showed higher rates of current cannabis use and frequency of
intake in unadjusted but not in adjusted analyses compared to
female ARMS patients. This finding is in line with a previous study
of our own group [26] and others that report no gender differences
regarding substance abuse in the prodromal phase of schizophre-
nia [2]. However, higher rates of substance abuse in men are found
in the general population [7] and in schizophrenia in particular [2].Our finding of higher rates of comorbid affective and anxiety
disorders in female ARMS patients contradicts a recent study on
ARMS patients, which has found no gender differences for affective
and anxiety disorders [11]. However, an earlier study found greater
rates of current depression and social anxiety in high-risk women
compared to men [28]. Furthermore, Pruessner et al. [29] also
found more depressive symptoms in high-risk women, but these
differences did not withstand correction for multiple testing. An
explanation may be that the self-report questionnaires used in the
study of Rietdijk et al. [28] have led to an overestimation of the
number of patients with an anxiety disorder or depression. Most
importantly, our results are in line with epidemiological studies on
depression and anxiety in the general population, which found
female/male prevalence ratios of 2:1, respectively [30,31]. ARMS
patients in this respect thus do not seem to differ from the general
population.
Our finding of no gender difference in terms of level of
functioning is in accordance with previous studies [2].
A strength of our study is that we examined gender differences
with several, well established instruments to assess a broad range
of symptomatology. Rater trainings have been used to ensure that
all raters administering the rating scales in the same way.
Furthermore, the multicentre design of our study might have
contributed to heterogeneity in our sample through, for example,
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potency of cannabis products in different study centres. We have
therefore included random intercepts that varied across study
centres in all our models. Finally, this is one of the first studies to
investigate gender differences in symptomatology in an ARMS
sample of this size.
However, although data were collected by well-trained
interviewers using standardized questionnaires and well-
established diagnostic criteria, this does not completely eliminate
possible gender-specific biases, e.g. of questionnaires and inter-
viewing techniques, of self-reporting, or interpreting patient
information, of applying diagnostic criteria or attributing diagnos-
tic labels [32]. Furthermore, this study concentrates on the age
group of 18–35 years with the consequence that especially boys,
who are at-risk state presumably before age 18 and women with
later age of onset are missed. An additional limitation could be that
our sample may not be representative for the overall population of
help-seeking patients since we do not know whether all ARMS
patients in the relevant catchment areas were searching help and
came to an early detection service. A recent study found a
significantly different gender distribution between ARMS and first
episode psychosis (FEP) patients with a greater proportion of males
in FEP cohorts than in clinical high-risk cohorts [33]. The authors
presume that ARMS men are probably less likely to be help-seeking
or less ‘literate’ of symptoms of mental illness which could lead to
an under-representation of men in existing clinical high-risk
services. Lastly, it should be noted that ARMS patients represent a
heterogeneous patient group with only about 20–35% developing
frank psychosis [34,35] and about one third having a clinical
remission within the first two years of the follow-up [36]. Hence,
gender differences reported in this study cannot be generalized to
patients being in true prodromal state for psychosis.
Taken together, our findings indicate that gender differences in
symptomatology – if present at all – are so small that they are likely
not to be clinically meaningful.
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